scholarly journals A real-world evidence of efficacy of palliative gastrectomy plus chemotherapy in metastatic gastric cancer patients

2019 ◽  
Vol Volume 11 ◽  
pp. 3993-4003
Author(s):  
Lu-Ping Yang ◽  
Zi-Xian Wang ◽  
Ming-Ming He ◽  
Hao-Xiang Wu ◽  
Shu-Qiang Yuan ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Real World ◽  
Metastatic Gastric Cancer ◽  
Palliative Gastrectomy ◽  
Real World Evidence ◽  
Gastric Cancer Patients

scholarly journals Palliative Gastrectomy Prolongs Survival of Metastatic Gastric Cancer Patients with Normal Preoperative CEA or CA19-9 Values: A Retrospective Cohort Study

2016 ◽  
Vol 2016 ◽  
pp. 1-9 ◽  
Author(s):  
Chang-Fang Chiu ◽  
Horng-Ren Yang ◽  
Mei-Due Yang ◽  
Long-Bin Jeng ◽  
Tse-Yen Yang ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Overall Survival ◽  
Prognostic Factors ◽  
Cancer Patients ◽  
Performance Status ◽  
Metastatic Gastric Cancer ◽  
Palliative Gastrectomy ◽  
Cast Doubt ◽  
Gastric Cancer Patients ◽  
Univariate Analyses

Background. Palliative gastrectomy has been suggested to improve survival of patients with metastatic gastric cancer, but limitations in study design and availability of robust prognostic factors have cast doubt on the overall merit of this procedure. Methods. The characteristics and clinical outcomes of 173 patients diagnosed between 2008 and 2012 were analyzed to determine the value of palliative gastrectomy and to identify potential prognostic factors. Results. Median overall patient survival was 6.5 months. To attenuate potential selection bias, patients with adequate performance and survival time of ≥ 2 months since diagnosis were included for risk factor analysis (n=137). The median overall survival was longer for patients who were younger than 60 years, had better performance status (8.7 versus 6.4 months, P=0.015), received systemic chemotherapy, or had palliative gastrectomy in univariate analyses. Gastrectomy (P=0.002) remained statistically significant in multivariate analyses. Subgroup analysis showed that patients aged < 60 years, CEA < 5 ng/mL or CA19-9 < 35 U/mL, obtained a survival advantage from palliative gastrectomy. In fact, palliative gastrectomy doubled overall survival for patients who had normal CEA and/or normal CA19-9. Conclusions. Palliative gastrectomy prolongs the survival of metastatic gastric cancer patients with normal CEA and/or CA19-9 level at the time of diagnosis.

scholarly journals Impact of Palliative Gastrectomy in Patients with Incurable Gastric Cancer

Medicina ◽  
2021 ◽  
Vol 57 (3) ◽  
pp. 198
Author(s):  
Ji Yeon Park ◽  
Byunghyuk Yu ◽  
Ki Bum Park ◽  
Oh Kyoung Kwon ◽  
Seung Soo Lee ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Overall Survival ◽  
Cancer Patients ◽  
Tumor Resection ◽  
Palliative Resection ◽  
Primary Tumors ◽  
Palliative Intent ◽  
Palliative Gastrectomy ◽  
Gastric Cancer Patients ◽  
The Impact

Background and Objectives: The prognosis of metastatic or unresectable gastric cancer is dismal, and the benefits of the palliative resection of primary tumors with noncurative intent remain controversial. This study aimed to evaluate the impact of palliative gastrectomy (PG) on overall survival in gastric cancer patients. Materials and Methods: One hundred forty-eight gastric cancer patients who underwent PG or a nonresection (NR) procedure between January 2011 and 2017 were retrospectively reviewed to select and analyze clinicopathological factors that affected prognosis. Results: Fifty-five patients underwent primary tumor resection with palliative intent, and 93 underwent NR procedures owing to the presence of metastatic or unresectable disease. The PG group was younger and more female dominant. In the PG group, R1 and R2 resection were performed in two patients (3.6%) and 53 patients (96.4%), respectively. The PG group had a significantly longer median overall survival than the NR group (28.4 vs. 7.7 months, p < 0.001). Multivariate analyses revealed that the overall survival was significantly better after palliative resection (hazard ratio (HR), 0.169; 95% confidence interval (CI), 0.088–0.324; p < 0.001) in patients with American Society of Anesthesiologists Physical Status (ASA) scores ≤1 (HR, 0.506; 95% CI, 0.291–0.878; p = 0.015) and those who received postoperative chemotherapy (HR, 0.487; 95% CI, 0.296–0.799; p = 0.004). Among the patients undergoing palliative resection, the presence of <15 positive lymph nodes was the only significant predictor of better overall survival (HR, 0.329; 95% CI, 0.121–0.895; p = 0.030). Conclusions: PG might lead to the prolonged survival of certain patients with incurable gastric cancer, particularly those with less-extensive lymph-node metastasis.

scholarly journals P21-Activated Kinase 4 Overexpression in Metastatic Gastric Cancer Patients

2011 ◽  
Vol 4 (6) ◽  
pp. 345-349 ◽  
Author(s):  
Hee Kyung Ahn ◽  
Jiryeon Jang ◽  
Jeeyun Lee ◽  
Hoon Park Se ◽  
Joon Oh Park ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Metastatic Gastric Cancer ◽  
P21 Activated Kinase ◽  
Gastric Cancer Patients

scholarly journals Simple combinations of 5-FU pathway genes predict the outcome of metastatic gastric cancer patients treated by S-1

2006 ◽  
Vol 119 (8) ◽  
pp. 1927-1933 ◽  
Author(s):  
Wataru Ichikawa ◽  
Takehiro Takahashi ◽  
Kenichi Suto ◽  
Yoshinori Shirota ◽  
Zenro Nihei ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Metastatic Gastric Cancer ◽  
Gastric Cancer Patients

Patient-reported symptoms in metastatic gastric cancer patients in the last 6 months of life

2020 ◽  
Vol 29 (1) ◽  
pp. 515-524 ◽  
Author(s):  
Lev D. Bubis ◽  
Victoria Delibasic ◽  
Laura E. Davis ◽  
Yunni Jeong ◽  
Kelvin Chan ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Metastatic Gastric Cancer ◽  
Patient Reported ◽  
Gastric Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document